City of Hope

University of California

Columbia University

California Institute of Technology

National and Kapodistrian University of Athens

Other

University of Southern California

David A Horne

Jun Xie

Sangkil Nam

Christopher Lincoln

Richard Jove

John C Williams

Yuelong Ma

Larry Eugene Overman

Hongzhi Li

Robert J Hickey

Linda H Malkas

Judith L Campbell

Li Zheng

Binghui Shen

Kenneth Karanja

Kenichi Yakushijin

Long Gu

Heng Wei Chang

Krzysztof Bzymek

Angela L Perkins Harki

John E Shively

Samuel Rahbar

Sanjay Awasthi

Kendra Nicole Avery

Cindy Zer

James Lester Figarola

Joshua Michael Donaldson

Rachael Mooney

Yate-Ching Yuan

Marcus Baumann

Claudia Kowolik

Monika Polewski

George Somlo

Lixin Yang

Wendong Huang

Yun Yen

Rongzhen Xu

Sharad S Singhal

Nikolaos Lougiakis

Leila Su

Junfeng Li

Ravi Salgia

Zijie Sun

Nicolas Gaboriaud-Kolar

Alexios Leandros Skaltsounis

Jyotasana Singhal

Shubbir Ahmed

Bing-Sen Zhou

Brad Loertscher

Hiroshi Suzuki

Hitoshi Shimizu

Peter Conti

Yang Su

Zibo Li

Daniela Castanotto

Yuan Chen

Lin Li

Alexios-Leandros Skaltsounis

Nicole Pouli

Yi-Jia Li

Cy Aaron Stein

Fumiko Y Yakushijin

Panagiotis Gerolymatos

Noboru Kubodera

Zhanhong Wu

Shih-Hsun Chen

Xiaochun Yu

Shuanlong Liu

Rajiv Nallu

Binfeng Zhang

Senlin Xu

Michael Kahn

Panagiotis Marakos

Marina Kritsanida

Hua Yu

Angela L Perkins-Harki

Disclosed and provided herein are, inter alia, compounds of formula (Ia), (Ib), or (Ic): or pharmaceutically acceptable salts or stereoisomers thereof, and use thereof in methods for modulating CREB binding protein (CBP)/catenin signaling pathway activity and treating CBP/β-catenin mediated disorders.

Substituted pyrazino[2,1-c][1,2,4]triazines as Wnt/CBP/catenin signaling pathway inhibitors

Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

PCNA inhibitors

Provided herein are, inter alia, methods of treating cancer using compounds of the invention.

Berbamine derivatives and methods of use thereof

Provided herein are solution formulations of CX-011 and related methods for making solution formulations of CX-011. Also provided are methods of treating an inflammatory disorder, such as osteoarthritis, or cancer in a subject in need thereof by administering an effective amount of the solution formulations of CX-011.

Solution formulations of CX-011

Disclosed herein are compositions and methods for treating cancer, FLT3-AML, and CML.

5-Bromo-indirubins

Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.

Mechanically interlocking complexes

Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.

PARG inhibitors and method of use thereof

Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

DNA2 inhibitors for cancer treatment

Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

T-cell lymphoma treatments

Provided herein are, inter alia, methods useful for delivering nucleic acids and kinase inhibitors to a cell. The methods provided herein include the delivery of therapeutic nucleic acids to cancer cells by contacting a cancer cell with a kinase inhibitor and a therapeutic nucleic acid. The methods provided herein are therefore, inter alia, useful for the treatment of cancer.

TKI permeability enhancers

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Compound for treating cancer and diabetes

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Dithio ETP derivatives

Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Methods of treating advanced prostate cancer

Growing community of inventors

Duarte, CA, United States of America

David A Horne